For US Healthcare Professionals

Request Information
Consider her next treatment option together with MARGENZA.

What will be the next treatment option for your patients with HER2‑positive mBC?

See Guidelines

MARGENZA (margetuximab-cmkb) plus chemotherapy is indicated for the treatment of adult patients with HER2‑positive mBC who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.

Fc=fragment crystallizable; FDA=US Food and Drug Administration; HER2-positive=human epidermal growth factor receptor 2 positive; mAb=monoclonal antibody; mBC=metastatic breast cancer; MOA=mechanism of action; OS=overall survival.

References:

1. MARGENZA Prescribing Information. MacroGenics, Inc.

2. Musolino A, Gradishar WJ, Rugo HS, et al. Role of Fcγ receptors in HER2-targeted breast cancer therapy. J Immunother Cancer. Published online January 6, 2022. doi:10.1136/jitc-2021-003171